Cargando…
Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340518/ https://www.ncbi.nlm.nih.gov/pubmed/30713717 http://dx.doi.org/10.1136/rmdopen-2018-000701 |
| _version_ | 1783388809063301120 |
|---|---|
| author | Blokland, Sofie L M Hillen, Maarten R Wichers, Catharina G K Zimmermann, Maili Kruize, Aike A Radstake, Timothy R D J Broen, Jasper C A van Roon, Joel A G |
| author_facet | Blokland, Sofie L M Hillen, Maarten R Wichers, Catharina G K Zimmermann, Maili Kruize, Aike A Radstake, Timothy R D J Broen, Jasper C A van Roon, Joel A G |
| author_sort | Blokland, Sofie L M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6340518 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63405182019-02-02 Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? Blokland, Sofie L M Hillen, Maarten R Wichers, Catharina G K Zimmermann, Maili Kruize, Aike A Radstake, Timothy R D J Broen, Jasper C A van Roon, Joel A G RMD Open Sjögren Syndrome BMJ Publishing Group 2019-01-11 /pmc/articles/PMC6340518/ /pubmed/30713717 http://dx.doi.org/10.1136/rmdopen-2018-000701 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Sjögren Syndrome Blokland, Sofie L M Hillen, Maarten R Wichers, Catharina G K Zimmermann, Maili Kruize, Aike A Radstake, Timothy R D J Broen, Jasper C A van Roon, Joel A G Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title_full | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title_fullStr | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title_full_unstemmed | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title_short | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| title_sort | increased mtorc1 activation in salivary gland b cells and t cells from patients with sjögren’s syndrome: mtor inhibition as a novel therapeutic strategy to halt immunopathology? |
| topic | Sjögren Syndrome |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340518/ https://www.ncbi.nlm.nih.gov/pubmed/30713717 http://dx.doi.org/10.1136/rmdopen-2018-000701 |
| work_keys_str_mv | AT bloklandsofielm increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT hillenmaartenr increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT wicherscatharinagk increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT zimmermannmaili increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT kruizeaikea increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT radstaketimothyrdj increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT broenjasperca increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology AT vanroonjoelag increasedmtorc1activationinsalivaryglandbcellsandtcellsfrompatientswithsjogrenssyndromemtorinhibitionasanoveltherapeuticstrategytohaltimmunopathology |